Affordable Access

Publisher Website

Vasopressin V2Receptor Blockade WithTolvaptanVersus Fluid Restriction in the Treatment of Hyponatremia

Authors
Journal
The American Journal of Cardiology
0002-9149
Publisher
Elsevier
Publication Date
Volume
97
Issue
7
Identifiers
DOI: 10.1016/j.amjcard.2005.10.050

Abstract

Hyponatremia is common and is associated with a poor prognosis. Traditional management with fluid restriction is difficult to maintain, and it is often ineffective. The objective of this study was to determine the effect of tolvaptan versus fluid restriction on serum sodium concentration. The study was a prospective, multicenter, randomized, active-controlled, open-label trial. Twenty-eight hospitalized subjects with serum sodium <135 mmol/L were enrolled in the study. After a 2-day run-in period, subjects were randomized 2:1 to tolvaptan alone (n = 17) or fluid restriction (1,200 ml/day) plus placebo (n = 11). Oral tolvaptan was started at 10 mg/day and increased to 60 mg/day as needed. Treatment was continued for up to 27 days, and follow-up continued for up to 65 days. The primary end point was the normalization of serum sodium, defined as >135 mmol/L or a ≥10% increase from baseline. At the last inpatient visit, serum sodium had increased by 5.7 ± 3.2 mmol/L in the tolvaptan group and 1.0 ± 4.7 mmol/L in the fluid restriction group (p = 0.0065). No differences in adverse events were observed between the groups. In conclusion, tolvaptan appears to be more effective than fluid restriction at correcting hyponatremia in hospitalized subjects, without an increase in adverse events.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Vasopressin v(2) receptor blockade with tolvaptan...

on The American Journal of Cardio... Apr 01, 2006

Vasopressin V2-receptor antagonists: panaceas for...

on Current opinion in nephrology... September 1997

Aquaretic and hormonal effects of a vasopressin V2...

on European Journal of Pharmacolo... Jan 01, 2000

Lixivaptan, a non-peptide vasopressin V2 receptor...

on IDrugs : the investigational d... November 2010
More articles like this..